ABROCITINIB treatment can be personalized in moderate-to-severe atopic dermatitis using flexible dosing to meet disease trajectory.
Abrocitinib Treatment with Flexible Dosing
A narrative review explores how abrocitinib, an oral Janus kinase 1 (JAK1) inhibitor approved for moderate-to-severe atopic dermatitis, may be tailored to a patient’s disease course through flexible dosing. The authors highlight supportive evidence from Phase 2 and Phase 3 randomized clinical trials within the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) clinical development program, which demonstrated efficacy and safety in adults and adolescents with moderate-to-severe atopic dermatitis. The review’s focus is practical: how clinicians can use dosing adjustments as part of individualized care and joint provider patient decision making, while keeping benefit risk considerations central.
Maintaining Control at the Lowest Effective Dose
Atopic dermatitis is chronic and relapsing, commonly presenting with intense itch, erythema, and eczematous lesions that can significantly affect quality of life and drive long-term treatment needs. The review emphasizes dosing flexibility with a clear goal of maintaining control using the lowest effective abrocitinib dose. When disease activity increases, the authors describe escalation as a tool to regain control, followed by dose reduction when stability returns. This approach is presented as a way to align abrocitinib treatment with real world fluctuations in symptoms, rather than treating dosing as fixed across time.
Safety Data Reflect Current Dose
The authors report that safety data indicate the incidence of treatment-emergent adverse events is reflective of the current abrocitinib dosage. They also state there is no carry-over safety risk from a previous higher dosage after a patient steps down to a lower dose. In the context of flexible dosing, this supports dose reduction once adequate control is achieved, with safety expectations guided by the present dose rather than prior dosing history. Overall, the review concludes that abrocitinib treatment is a valuable option for moderate-to-severe atopic dermatitis that can be adapted to individual patient needs across flare control and maintenance while aiming to minimize safety risks.
Reference: Silverberg JI et al. Tailoring Abrocitinib Treatment for Moderate-to-Severe Atopic Dermatitis to Patient Disease Course: A Narrative Review. Dermatol Ther (Heidelb). 2025;doi: 10.1007/s13555-025-01618-5.
